芪蛭胶囊联合辛伐他汀治疗高脂血症的临床研究
|
摘要
目的观察芪蛭胶囊联合辛伐他汀片治疗高脂血症的临床疗效。方法选取2017年3月—2018年12月天津市第四中心医院收治的236例高脂血症患者作为研究对象,按治疗方案随机将患者分为对照组和治疗组,每组各118例。对照组每晚睡前口服辛伐他汀片,20mg/次,1次/d;治疗组在对照组治疗的基础上口服芪蛭胶囊,0.8g/次,3次/d。两组患者均连续用药8周。观察两组患者的临床疗效,比较两组治疗前后的血脂水平、血液流变学指标和血管内皮功能。结果治疗后,对照组和治疗组的总有效率分别为80.51%、93.22%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平明显下降,高密度脂蛋白胆固醇(HDL-C)明显升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血脂水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组的全血高切黏度(HBV)、全血中切黏度(MBV)、全血低切黏度(LBV)和血浆黏度(PV)水平明显下降,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血液流变学指标水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组的内皮素-1(ET-1)水平明显下降,一氧化氮(NO)、血管舒张功能(FMD)显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血管内皮功能显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论芪蛭胶囊联合辛伐他汀片治疗高脂血症具有较好的临床疗效,能够显著降低患者血脂水平、促进血管内皮功能和血液流变学明显改善,具有一定的临床推广应用价值。
Objective To observe the clinical effects of Qizhi Capsules combined with Simvastatin Tablets in treatment of hyperlipidemia. Methods Patients(236 cases) with hyperlipidemia in Tianjin 4th Central Hospital from March 2017 to December2018 were divided into control and treatment groups according to the treatment plan, and each group had 118 cases. Patients in the control group were po administered with Simvastatin Tablets before going to bed, 20 mg/time, once daily. Patients in the treatment group were po administered with Qizhi Capsules on the basis of control group, 0.8 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy, and the blood lipid levels, hemorheology indexes, and vascular endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.51% and 93.22%, respectively, and there were differences between two groups(P < 0.05). After treatment, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group(P < 0.05). After treatment, blood lipid levels in the treatment group were better than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the levels of HBV, MBV, LBV, and PV in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the hemorheology indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, ET-1 in two groups were significantly decreased, but NO and FMD were increased, and there were differences in the same group(P < 0.05). After treatment, the vascular endothelial function levels in the treatment group were better than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Qizhi Capsules combined with Simvastatin Tablets has a good clinical effect in treatment of hyperlipidemia, can significantly reduce blood lipid levels, and promote vascular endothelial function and hemorheology, which has a certain clinical application value.
Objective To observe the clinical effects of Qizhi Capsules combined with Simvastatin Tablets in treatment of hyperlipidemia. Methods Patients(236 cases) with hyperlipidemia in Tianjin 4th Central Hospital from March 2017 to December2018 were divided into control and treatment groups according to the treatment plan, and each group had 118 cases. Patients in the control group were po administered with Simvastatin Tablets before going to bed, 20 mg/time, once daily. Patients in the treatment group were po administered with Qizhi Capsules on the basis of control group, 0.8 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy, and the blood lipid levels, hemorheology indexes, and vascular endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.51% and 93.22%, respectively, and there were differences between two groups(P < 0.05). After treatment, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group(P < 0.05). After treatment, blood lipid levels in the treatment group were better than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the levels of HBV, MBV, LBV, and PV in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the hemorheology indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, ET-1 in two groups were significantly decreased, but NO and FMD were increased, and there were differences in the same group(P < 0.05). After treatment, the vascular endothelial function levels in the treatment group were better than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Qizhi Capsules combined with Simvastatin Tablets has a good clinical effect in treatment of hyperlipidemia, can significantly reduce blood lipid levels, and promote vascular endothelial function and hemorheology, which has a certain clinical application value.
引文
[1]徐恩,温海霞.脑血管病危险因素及其干预管理[J].中国现代神经疾病杂志,2015,15(1):20-26.
[2]周皖舒,彭年春,时立新,等.贵阳地区60岁以上老年人群心脑血管疾病危险因素研究[J].贵州医科大学学报,2016,41(8):935-938.
[3]胡大一.中国血脂异常与动脉粥样硬化性心血管疾病防控的新证据和新指南[J].中华心血管病杂志,2016,44(10):826-827.
[4]王君,席新龙,郑明娟,等.健康体检者颈动脉粥样硬化与同型半胱氨酸、血脂、血糖水平相关性研究[J].陕西医学杂志,2018,47(5):600-603.
[5]陈可冀,刘玥.2013 ACC/AHA胆固醇治疗指南更新要点解读与思考[J].中国中西医结合杂志,2014,34(2):136-137.
[6]焦峰军,李欢,任旭爱,等.芪蛭胶囊联合阿托伐他汀和依折麦布治疗老年冠心病合并高脂血症的疗效观察[J].现代药物与临床,2015,30(8):950-953.
[7]中国中西医结合学会心血管病专业委员会动脉粥样硬化与血脂异常专业组.血脂异常中西医结合诊疗专家共识[J].中国全科医学,2017,20(3):262-269.
[8]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:89.
[9]丛伟,杨秋.高脂血症防治新进展[J].中国综合临床,2004,20(6):571-572.
[10]任世存,杨如意.芪蛭胶囊对高脂血症大鼠的抗氧化作用[J].陕西中医,2007,28(10):1424-1426.
[11]彭彩亮,高嵩山,蒋宁.芪蛭胶囊治疗稳定性心绞痛的临床观察[J].黑龙江中医药,2014,43(5):19-20.
[12]栾尚顺,崔爱卿.TG、TC、HDL-c、LDL-c及动脉粥样硬化与血清中TB的关联性研究[J].中国医疗前沿,2009,4(18):63,66.
[13]叶林书,孙晓英,朱桐春,等.原发性高血压合并高脂血症患者血浆一氧化氮和内皮素含量的临床意义[J].医学理论与实践,2001,14(4):294-296.
[14]洪绍彩,梁衍时,尹瑞兴,等.高脂血症患者血管内皮舒张功能障碍的相关因素探讨[J].中国循环杂志,2003,18(1):43-45.
[15]旅朝霞,郭洪涛,刘巍立,等.ET-1及ET-1/NO比值在冠心病中的平衡关系[J].中华临床医学实践杂志,2006,5(6):511-512.
[16]雷宇春,李艺萍.高脂血症患者血液流变学指标分析[J].人民军医,2007,50(5):276-277.
[2]周皖舒,彭年春,时立新,等.贵阳地区60岁以上老年人群心脑血管疾病危险因素研究[J].贵州医科大学学报,2016,41(8):935-938.
[3]胡大一.中国血脂异常与动脉粥样硬化性心血管疾病防控的新证据和新指南[J].中华心血管病杂志,2016,44(10):826-827.
[4]王君,席新龙,郑明娟,等.健康体检者颈动脉粥样硬化与同型半胱氨酸、血脂、血糖水平相关性研究[J].陕西医学杂志,2018,47(5):600-603.
[5]陈可冀,刘玥.2013 ACC/AHA胆固醇治疗指南更新要点解读与思考[J].中国中西医结合杂志,2014,34(2):136-137.
[6]焦峰军,李欢,任旭爱,等.芪蛭胶囊联合阿托伐他汀和依折麦布治疗老年冠心病合并高脂血症的疗效观察[J].现代药物与临床,2015,30(8):950-953.
[7]中国中西医结合学会心血管病专业委员会动脉粥样硬化与血脂异常专业组.血脂异常中西医结合诊疗专家共识[J].中国全科医学,2017,20(3):262-269.
[8]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:89.
[9]丛伟,杨秋.高脂血症防治新进展[J].中国综合临床,2004,20(6):571-572.
[10]任世存,杨如意.芪蛭胶囊对高脂血症大鼠的抗氧化作用[J].陕西中医,2007,28(10):1424-1426.
[11]彭彩亮,高嵩山,蒋宁.芪蛭胶囊治疗稳定性心绞痛的临床观察[J].黑龙江中医药,2014,43(5):19-20.
[12]栾尚顺,崔爱卿.TG、TC、HDL-c、LDL-c及动脉粥样硬化与血清中TB的关联性研究[J].中国医疗前沿,2009,4(18):63,66.
[13]叶林书,孙晓英,朱桐春,等.原发性高血压合并高脂血症患者血浆一氧化氮和内皮素含量的临床意义[J].医学理论与实践,2001,14(4):294-296.
[14]洪绍彩,梁衍时,尹瑞兴,等.高脂血症患者血管内皮舒张功能障碍的相关因素探讨[J].中国循环杂志,2003,18(1):43-45.
[15]旅朝霞,郭洪涛,刘巍立,等.ET-1及ET-1/NO比值在冠心病中的平衡关系[J].中华临床医学实践杂志,2006,5(6):511-512.
[16]雷宇春,李艺萍.高脂血症患者血液流变学指标分析[J].人民军医,2007,50(5):276-277.